Latest News

Quanta Raises £27 Million to Prepare its Advanced Haemodialysis System SC+ for Launch.

Alcester, Warwickshire, UK, 3 November 2014: Quanta Fluid Solutions Ltd (“Quanta”) a pioneering developer of advanced haemodialysis systems, today announced that it has closed a fundraising of approximately £27 million. The funding round was led by ALIAD, the venture capital investment vehicle of Air Liquide SA (Paris: AI), and included participation by new investor...


Seroba Kernel is Pleased to Announce The Sale of Our Investee Company, Covagen.

Seroba Kernel is pleased to announce the sale of our investee company, Covagen AG. Covagen has been acquired by Cilag GmbH International, a part of the Janssen Pharmaceutical companies of the Johnson & Johnson Group. Seroba Kernel led a Series A extension investment into Covagen in 2010. Speaking about the sale of the company, Dr Daniel O’Mahony, partner with Seroba Kernel commented, “We...


Xention commences first phase 2 study of XEN-D0103 in atrial fibrillation.

CAMBRIDGE, UK – XENTION LTD. Sept 2nd, 2014. Seroba Kernel's investee company, 'Xention', the Cambridge-based biopharmaceutical company specialising in the discovery and development of ion channel-modulating drugs developing anti-arrhythmic drugs, announced today that the phase 2 development of its lead atrial fibrillation programme ("AF") is underway. In 2013, Xention...


< back to home page